Affymax (AFFY), Takeda Announce CMS Assigned Q-Code for OMONTYS(R) Injection

Article Stock Quotes (1) Comments (0)

Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceuticals U.S.A. today announced that the Centers for Medicare and Medicaid Services (CMS) has granted a unique product reimbursement code, or Q-code, for OMONTYS® (peginesatide) Injection. The OMONTYS-specific billing code, Q2047, will help streamline the billing process for dialysis organizations using OMONTYS. This new Q-code will become effective on July 1, 2012. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population in the United States.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Affymax (AFFY) CEO to Be Replaced by Rep of Restructuring Firm
• James River Coal (JRCC) Higher; Announces Private Exchange Pacts on Notes
• Oramed Pharma (ORMP) OK'd by FDA for ORMD-0801 IND

Create E-mail Alert Related Categories

Corporate News

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?